Search bioRxiv⌕ Search

Biology subjects

Durocher, E.

Publications and source records attributed to Durocher, E..

3 recordsLinked to original sources

Tumour architecture shapes polarized epithelial states that predict survival in high-grade serous ovarian cancer

Epithelial heterogeneity defines high-grade serous ovarian carcinoma (HGSC), yet principles that generate this diversity within and across tumours remain unclear. Integrating single-cell RNA sequencing (scRNA-seq) data from 13 studies (1,980,703 cells, 371 samples), we resolve a dominant axis of secretory cell polarization spanning proliferative, progenitor-like SecA cells and quiescent SecB cells expressing a mucosal injury response program. Targeted spatial transcriptomics across 8 whole HGSC tissues and a 97-patient tissue microarray shows this axis is spatially deterministic: tumour architecture shapes a hypoxic gradient along which SecB cells localize to avascular, luminal regions, where HIF/NF-{kappa}B-driven survival and glycolysis displace the mitogenic signalling of SecA. Within this niche, SecB cells rewire adhesion, ECM-remodelling, and immune-regulatory programs. Transcriptionally reprogrammed macrophages are enriched in this niche, while lymphocytes are excluded or dysfunctional. These cells assemble a coordinated multicellular niche poised for dissemination. SecB cells are enriched both in ascites and after chemotherapy, and are progressively lost in patient-derived organoids, only partially restored by IFN{gamma}, suggesting SecB is environmentally programmed rather than clonally fixed. SecB proportion independently predicts worse overall (HR = 1.31, p = 0.023) and progression-free survival (HR = 1.28, p = 0.011). Tumour architecture is thus a primary axis of malignant identity in HGSC, coupling microenvironment, cell state, and immune niche to clinical outcomes.

cancer biology↗

Development of 3-in-1 nanotherapeutic strategies for ovarian cancer

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=145 SRC="FIGDIR/small/604002v1_ufig1.gif" ALT="Figure 1"> View larger version (43K): org.highwire.dtl.DTLVardef@1c2d3e3org.highwire.dtl.DTLVardef@1e4e73eorg.highwire.dtl.DTLVardef@109aceeorg.highwire.dtl.DTLVardef@387843_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOTOCC_FLOATNO C_FIG Among gynecological cancers, ovarian cancer causes the most fatality. Platin-based chemotherapy is the primary therapeutic option, but it is limited by a variety of drug resistance mechanisms. Ovarian cancer is a complex and challenging disease to treat, and combination approaches have shown stronger efficacy than a single drug alone. However, they still need to overcome challenges, such as the non-selective distribution of drugs, and side effects caused by each drug in the combination. To overcome these issues, here we explored a 3-in-1 combination nanotherapeutic approach containing cisplatin, olaparib, and metformin for ovarian cancer. To encapsulate hydrophilic cisplatin and metformin inside the nanoparticle (NP) core, we developed cisplatin polymer prodrugs and metformin derivatives. Our results showed successful development of 3-in-1 NPs containing cisplatin, olaparib, and metformin, and they are stable in the physiological conditions. In vitro evaluation showed each agent in the 3-in-1 NPs is active and exerts therapeutic effects, contributing to ovarian cancer cell killing at lower concentrations. These results provide insight into developing novel nanotherapeutic strategies for improving ovarian cancer treatment.

bioengineering↗

Nanoparticles co-delivering siRNA and mRNA for simultaneous restoration and silencing of gene/protein expression in vitro and invivo

RNA-based agents such as siRNA, miRNA, and mRNA can selectively manipulate gene expression/proteins and have the potential to revolutionize the current therapeutic strategies for various diseases, including cancer. To address the poor stability and inherent limitations of RNA agents, nanoparticle (NP) platforms have been developed to deliver functional mRNA or siRNA inside the cells. Recent studies have focused on either siRNA to knock down proteins causing drug resistance or mRNA technology to introduce tumor suppressors. However, complex diseases like cancer need multi-targeted approaches to selectively target multiple gene expressions/proteins. In this proof-of-concept study, we developed co-delivery nanoparticles containing Luc-mRNA and siRNA-GFP as model RNA agents ((M+S)-NPs) and assessed their effects in vitro and in vivo. Our studies show that NPs can effectively deliver both functional mRNA and siRNA together, simultaneously impacting the expression of two genes/proteins in vitro. Additionally, after in vivo administration, co-delivery NPs successfully knocked down GFP while introducing luciferase in a TNBC mouse model, indicating our NPs have the potential to develop RNA-based anticancer therapeutics. These studies pave the way to develop RNA-based, multitargeted, multi-delivery approaches for complex diseases like cancer. TOC O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=90 SRC="FIGDIR/small/600196v1_ufig1.gif" ALT="Figure 1"> View larger version (37K): org.highwire.dtl.DTLVardef@1668ae2org.highwire.dtl.DTLVardef@1283491org.highwire.dtl.DTLVardef@9336daorg.highwire.dtl.DTLVardef@f654c5_HPS_FORMAT_FIGEXP M_FIG C_FIG

bioengineering↗